<p>隨着全球市場在消費者通脹上升和企業盈利強勁的複雜環境中航行，像標準普爾 500 指數和納斯達克綜合指數這樣的指數已達到新高，主要受關鍵行業強勁表現的推動。在這種經濟環境中，識別被低估的股票可以為尋求利用市場價格與內在價值之間差異的投資者提供潛在機會。</p>
<h3>基於現金流的十大被低估股票</h3>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名稱</strong></td>
<td><strong>當前價格</strong></td>
<td><strong>公允價值（估計）</strong></td>
<td><strong>折扣（估計）</strong></td>
</tr>
<tr>
<td>Surgical Science Sweden (OM:SUS)</td>
<td>SEK148.40</td>
<td>SEK294.49</td>
<td>49.6%</td>
</tr>
<tr>
<td>SpiderPlus (TSE:4192)</td>
<td>¥499.00</td>
<td>¥994.04</td>
<td>49.8%</td>
</tr>
<tr>
<td>RVRC Holding (OM:RVRC)</td>
<td>SEK45.68</td>
<td>SEK90.96</td>
<td>49.8%</td>
</tr>
<tr>
<td>Polaris Holdings (TSE:3010)</td>
<td>¥216.00</td>
<td>¥428.07</td>
<td>49.5%</td>
</tr>
<tr>
<td>Hugel (KOSDAQ:A145020)</td>
<td>₩351500.00</td>
<td>₩698441.84</td>
<td>49.7%</td>
</tr>
<tr>
<td>HDC Hyundai Development (KOSE:A294870)</td>
<td>₩23200.00</td>
<td>₩46090.66</td>
<td>49.7%</td>
</tr>
<tr>
<td>Grupo Hotelero Santa Fe. de (BMV:HOTEL *)</td>
<td>MX$3.60</td>
<td>MX$7.18</td>
<td>49.9%</td>
</tr>
<tr>
<td>Green Oleo (BIT:GRN)</td>
<td>€0.79</td>
<td>€1.57</td>
<td>49.8%</td>
</tr>
<tr>
<td>ATON Green Storage (BIT:ATON)</td>
<td>€2.13</td>
<td>€4.22</td>
<td>49.5%</td>
</tr>
<tr>
<td>Atea (OB:ATEA)</td>
<td>NOK143.00</td>
<td>NOK284.22</td>
<td>49.7%</td>
</tr>
</tbody>
</table>
<p>點擊這裏查看我們基於現金流的 469 只被低估全球股票的完整列表。</p>
<p>在這裏，我們突出顯示了我們篩選器中一些首選股票的子集。</p>
<h2>愛博醫療科技（北京）（SHSE:688050）</h2>
<p><strong>概述：</strong> 愛博醫療科技（北京）有限公司在醫療技術領域運營，專注於開發和製造眼科醫療設備，市值為 136.2 億人民幣。</p>
<p><strong>運營：</strong> 該公司主要通過其醫療產品部門產生收入，金額為 14.6 億人民幣。</p>
<p><strong>公允價值的估計折扣：</strong> 29.9%</p>
<p>愛博醫療科技（北京）的交易價格為 72.37 元，顯著低於其估計的公允價值 103.21 元，基於現金流顯示出潛在的低估。儘管最近每股股息減少至 0.35 元，但公司預計年收入增長 22.9%，年盈利增長 24.3%，均超過中國市場平均水平。分析師預計股價將大幅上漲 65.8%。</p>
<ul>
<li>我們的綜合增長報告提出愛博醫療科技（北京）有望實現顯著的財務增長。</li>
<li>通過閲讀我們的健康報告，深入瞭解愛博醫療科技（北京）的資產負債表。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/dc20de00-78ea-4048-94bf-72044b6428d6/chart/dcf/query-dGhlbWU9bGlnaHQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/dc20de00-78ea-4048-94bf-72044b6428d6/chart/dcf/query-dGhlbWU9bGlnaHQ"/></p>
<p>SHSE:688050 截至 2025 年 7 月的折現現金流</p>
<h2>Nayax (TASE:NYAX)</h2>
<p><strong>概述：</strong> Nayax Ltd.是一家金融科技公司，為各地區的自動自助零售商和商家提供全面解決方案，市值為 57.8 億新謝克爾。</p>
<p><strong>運營：</strong> 公司的收入主要來自其互聯網軟件和服務部門，產生了 3.3116 億美元。</p>
<p><strong>公允價值的估計折扣：</strong> 18.5%</p>
<p>Nayax 的交易價格為 156.5 新謝克爾，低於其估計的公允價值 191.96 新謝克爾，顯示出基於現金流的低估。該公司最近實現盈利，並預計年盈利增長 57.4%，超過以色列市場平均水平。預計收入將以每年 22.3% 的速度增長，得益於與 Lynkwell 在北美電動車充電解決方案方面的戰略合作，並重申 2025 年顯著收入增長的指導。</p>
<ul>
<li>我們編制的增長報告表明 Nayax 的未來前景可能向好。</li>
<li>通過我們的綜合財務健康報告，深入瞭解 Nayax 的複雜情況。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/9596c81c-53d8-4dbe-bd4f-a13422d8182c/chart/dcf/query-dGhlbWU9bGlnaHQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/9596c81c-53d8-4dbe-bd4f-a13422d8182c/chart/dcf/query-dGhlbWU9bGlnaHQ"/></p>
<p>TASE:NYAX 截至 2025 年 7 月的折現現金流</p>
<h2>Rorze (TSE:6323)</h2>
<p><strong>概述：</strong> Rorze Corporation 專注於全球半導體和液晶顯示器生產的自動化系統的設計、開發、製造和銷售，市值為 3395.4 億日元。</p>
<p><strong>運營：</strong> 收入部門（以百萬日元計）：半導體生產自動化系統 680 億；液晶顯示器生產自動化系統 125 億。</p>
<p><strong>公允價值的估計折扣：</strong> 25.7%</p>
<p>Rorze 的交易價格為 1992 日元，低於其估計的公允價值 2681.68 日元，反映出基於現金流的低估。儘管最近利潤率從 23.4% 下降至 15.7%，但預計年盈利將以 16% 的速度增長，超過日本市場 7.6% 的增長率。該公司最近完成了價值 19.8 億日元的股票回購，可能在其股價在過去三個月的高波動中提升股東價值。</p>
<ul>
<li>我們最近的增長報告的見解表明 Rorze 的商業前景樂觀。</li>
<li>點擊這裏通過我們的詳細財務健康報告發現 Rorze 的細微差別。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/4d659f8c-73ac-4638-abf7-18dec4e4fb14/chart/dcf/query-dGhlbWU9bGlnaHQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/4d659f8c-73ac-4638-abf7-18dec4e4fb14/chart/dcf/query-dGhlbWU9bGlnaHQ"/></p>
<p>TSE:6323 截至 2025 年 7 月的折現現金流</p>
<h2>總結</h2>
<ul>
<li>深入瞭解我們基於現金流的 469 只被低估全球股票的完整目錄。</li>
<li>這些股票中有哪幾只在你的資產組合中？利用 Simply Wall St 的投資組合分析工具，全面瞭解它們的表現。</li>
<li>通過使用 Simply Wall St，加入聰明投資者的社區。它是免費的，並提供全球市場的專家級分析。</li>
</ul>
<h2>對其他選擇感興趣？</h2>
<ul>
<li>探索尚未獲得顯著分析師關注的高表現小型公司。</li>
<li>通過提供可靠收入來源的穩健分紅股票來多樣化你的投資組合，以應對潛在的市場動盪。</li>
<li>通過分析師和管理層的樂觀展望，推動你的投資組合中顯示出強勁增長潛力的公司。</li>
</ul>
<p><em>這篇來自 Simply Wall St 的文章具有一般性。<strong>我們僅基於歷史數據和分析師預測提供評論，採用無偏見的方法，我們的文章並不旨在提供財務建議。它不構成買賣任何股票的推薦，也未考慮您的目標或財務狀況。</strong> 我們旨在為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中沒有持倉。</em></p>

NYAX

愛博醫療

6323

<p>在消費者通脹上升和企業盈利強勁的背景下，幾隻全球股票被認為被低估。愛博醫療科技（SHSE:688050）目前交易價格為 72.37 元，低於其公允價值 103.21 元的 29.9%，預計收入增長為 22.9%。Nayax Ltd.（TASE:NYAX）顯示出 18.5% 的折扣，交易價格為 156.5 新謝克爾，預計盈利增長為 57.4%。Rorze Corporation（TSE:6323）目前交易價格為 1992 日元，低於其公允價值的 25.7%，預計盈利增長為 16%。根據現金流分析，這些股票提供了潛在的投資機會</p>

<p>As global markets navigate a complex landscape marked by rising consumer inflation and robust corporate earnings, indices like the S&amp;P 500 and Nasdaq Composite have reached new highs, driven by strong performance in key sectors. Amidst this economic environment, identifying undervalued stocks can offer potential opportunities for investors seeking to capitalize on discrepancies between market price and intrinsic value.</p>
<div class="lb-trans"><p>隨着全球市場在消費者通脹上升和企業盈利強勁的複雜環境中航行，像標準普爾 500 指數和納斯達克綜合指數這樣的指數已達到新高，主要受關鍵行業強勁表現的推動。在這種經濟環境中，識別被低估的股票可以為尋求利用市場價格與內在價值之間差異的投資者提供潛在機會。</p>
</div><h3>Top 10 Undervalued Stocks Based On Cash Flows</h3>
<div class="lb-trans"><h3>基於現金流的十大被低估股票</h3>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Name</strong></td>
<td><strong>Current Price</strong></td>
<td><strong>Fair Value (Est)</strong></td>
<td><strong>Discount (Est)</strong></td>
</tr>
<tr>
<td>Surgical Science Sweden (OM:SUS)</td>
<td>SEK148.40</td>
<td>SEK294.49</td>
<td>49.6%</td>
</tr>
<tr>
<td>SpiderPlus (TSE:4192)</td>
<td>¥499.00</td>
<td>¥994.04</td>
<td>49.8%</td>
</tr>
<tr>
<td>RVRC Holding (OM:RVRC)</td>
<td>SEK45.68</td>
<td>SEK90.96</td>
<td>49.8%</td>
</tr>
<tr>
<td>Polaris Holdings (TSE:3010)</td>
<td>¥216.00</td>
<td>¥428.07</td>
<td>49.5%</td>
</tr>
<tr>
<td>Hugel (KOSDAQ:A145020)</td>
<td>₩351500.00</td>
<td>₩698441.84</td>
<td>49.7%</td>
</tr>
<tr>
<td>HDC Hyundai Development (KOSE:A294870)</td>
<td>₩23200.00</td>
<td>₩46090.66</td>
<td>49.7%</td>
</tr>
<tr>
<td>Grupo Hotelero Santa Fe. de (BMV:HOTEL *)</td>
<td>MX$3.60</td>
<td>MX$7.18</td>
<td>49.9%</td>
</tr>
<tr>
<td>Green Oleo (BIT:GRN)</td>
<td>€0.79</td>
<td>€1.57</td>
<td>49.8%</td>
</tr>
<tr>
<td>ATON Green Storage (BIT:ATON)</td>
<td>€2.13</td>
<td>€4.22</td>
<td>49.5%</td>
</tr>
<tr>
<td>Atea (OB:ATEA)</td>
<td>NOK143.00</td>
<td>NOK284.22</td>
<td>49.7%</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名稱</strong></td>
<td><strong>當前價格</strong></td>
<td><strong>公允價值（估計）</strong></td>
<td><strong>折扣（估計）</strong></td>
</tr>
<tr>
<td>Surgical Science Sweden (OM:SUS)</td>
<td>SEK148.40</td>
<td>SEK294.49</td>
<td>49.6%</td>
</tr>
<tr>
<td>SpiderPlus (TSE:4192)</td>
<td>¥499.00</td>
<td>¥994.04</td>
<td>49.8%</td>
</tr>
<tr>
<td>RVRC Holding (OM:RVRC)</td>
<td>SEK45.68</td>
<td>SEK90.96</td>
<td>49.8%</td>
</tr>
<tr>
<td>Polaris Holdings (TSE:3010)</td>
<td>¥216.00</td>
<td>¥428.07</td>
<td>49.5%</td>
</tr>
<tr>
<td>Hugel (KOSDAQ:A145020)</td>
<td>₩351500.00</td>
<td>₩698441.84</td>
<td>49.7%</td>
</tr>
<tr>
<td>HDC Hyundai Development (KOSE:A294870)</td>
<td>₩23200.00</td>
<td>₩46090.66</td>
<td>49.7%</td>
</tr>
<tr>
<td>Grupo Hotelero Santa Fe. de (BMV:HOTEL *)</td>
<td>MX$3.60</td>
<td>MX$7.18</td>
<td>49.9%</td>
</tr>
<tr>
<td>Green Oleo (BIT:GRN)</td>
<td>€0.79</td>
<td>€1.57</td>
<td>49.8%</td>
</tr>
<tr>
<td>ATON Green Storage (BIT:ATON)</td>
<td>€2.13</td>
<td>€4.22</td>
<td>49.5%</td>
</tr>
<tr>
<td>Atea (OB:ATEA)</td>
<td>NOK143.00</td>
<td>NOK284.22</td>
<td>49.7%</td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 469 stocks from our Undervalued Global Stocks Based On Cash Flows screener.</p>
<div class="lb-trans"><p>點擊這裏查看我們基於現金流的 469 只被低估全球股票的完整列表。</p>
</div><p>Here we highlight a subset of our preferred stocks from the screener.</p>
<div class="lb-trans"><p>在這裏，我們突出顯示了我們篩選器中一些首選股票的子集。</p>
</div><h2>Eyebright Medical Technology (Beijing) (SHSE:688050)</h2>
<div class="lb-trans"><h2>愛博醫療科技（北京）（SHSE:688050）</h2>
</div><p><strong>Overview:</strong> Eyebright Medical Technology (Beijing) Co., Ltd. operates in the medical technology sector, focusing on developing and manufacturing ophthalmic medical devices, with a market cap of CN¥13.62 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 愛博醫療科技（北京）有限公司在醫療技術領域運營，專注於開發和製造眼科醫療設備，市值為 136.2 億人民幣。</p>
</div><p><strong>Operations:</strong> The company generates revenue primarily from its Medical Products segment, amounting to CN¥1.46 billion.</p>
<div class="lb-trans"><p><strong>運營：</strong> 該公司主要通過其醫療產品部門產生收入，金額為 14.6 億人民幣。</p>
</div><p><strong>Estimated Discount To Fair Value:</strong> 29.9%</p>
<div class="lb-trans"><p><strong>公允價值的估計折扣：</strong> 29.9%</p>
</div><p>Eyebright Medical Technology (Beijing) is trading at CN¥72.37, significantly below its estimated fair value of CN¥103.21, presenting a potential undervaluation based on cash flows. Despite a recent dividend decrease to CNY 0.35 per share, the company forecasts robust revenue growth of 22.9% annually and earnings growth of 24.3%, both outpacing the Chinese market averages. Analysts anticipate a substantial stock price increase of 65.8%.</p>
<div class="lb-trans"><p>愛博醫療科技（北京）的交易價格為 72.37 元，顯著低於其估計的公允價值 103.21 元，基於現金流顯示出潛在的低估。儘管最近每股股息減少至 0.35 元，但公司預計年收入增長 22.9%，年盈利增長 24.3%，均超過中國市場平均水平。分析師預計股價將大幅上漲 65.8%。</p>
</div><ul>
<li>Our comprehensive growth report raises the possibility that Eyebright Medical Technology (Beijing) is poised for substantial financial growth.</li>
<li>Get an in-depth perspective on Eyebright Medical Technology (Beijing)'s balance sheet by reading our health report here.</li>
</ul>
<div class="lb-trans"><ul>
<li>我們的綜合增長報告提出愛博醫療科技（北京）有望實現顯著的財務增長。</li>
<li>通過閲讀我們的健康報告，深入瞭解愛博醫療科技（北京）的資產負債表。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/dc20de00-78ea-4048-94bf-72044b6428d6/chart/dcf/query-dGhlbWU9bGlnaHQ" alt="" original-src="https://images.simplywall.st/company/dc20de00-78ea-4048-94bf-72044b6428d6/chart/dcf?theme=light"/></p>
<p>SHSE:688050 Discounted Cash Flow as at Jul 2025</p>
<div class="lb-trans"><p>SHSE:688050 截至 2025 年 7 月的折現現金流</p>
</div><h2>Nayax (TASE:NYAX)</h2>
<div class="lb-trans"><h2>Nayax (TASE:NYAX)</h2>
</div><p><strong>Overview:</strong> Nayax Ltd. is a fintech company that provides comprehensive solutions for automated self-service retailers and merchants across various regions, with a market cap of ₪5.78 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> Nayax Ltd.是一家金融科技公司，為各地區的自動自助零售商和商家提供全面解決方案，市值為 57.8 億新謝克爾。</p>
</div><p><strong>Operations:</strong> The company's revenue primarily comes from its Internet Software and Services segment, which generated $331.16 million.</p>
<div class="lb-trans"><p><strong>運營：</strong> 公司的收入主要來自其互聯網軟件和服務部門，產生了 3.3116 億美元。</p>
</div><p><strong>Estimated Discount To Fair Value:</strong> 18.5%</p>
<div class="lb-trans"><p><strong>公允價值的估計折扣：</strong> 18.5%</p>
</div><p>Nayax is trading at ₪156.5, below its estimated fair value of ₪191.96, suggesting undervaluation based on cash flows. The company recently became profitable and forecasts strong earnings growth of 57.4% annually, outpacing the Israeli market average. Revenue is expected to grow by 22.3% per year, supported by strategic partnerships like the one with Lynkwell for EV charging solutions across North America and reaffirmed guidance for significant revenue increases in 2025.</p>
<div class="lb-trans"><p>Nayax 的交易價格為 156.5 新謝克爾，低於其估計的公允價值 191.96 新謝克爾，顯示出基於現金流的低估。該公司最近實現盈利，並預計年盈利增長 57.4%，超過以色列市場平均水平。預計收入將以每年 22.3% 的速度增長，得益於與 Lynkwell 在北美電動車充電解決方案方面的戰略合作，並重申 2025 年顯著收入增長的指導。</p>
</div><ul>
<li>The growth report we've compiled suggests that Nayax's future prospects could be on the up.</li>
<li>Navigate through the intricacies of Nayax with our comprehensive financial health report here.</li>
</ul>
<div class="lb-trans"><ul>
<li>我們編制的增長報告表明 Nayax 的未來前景可能向好。</li>
<li>通過我們的綜合財務健康報告，深入瞭解 Nayax 的複雜情況。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/9596c81c-53d8-4dbe-bd4f-a13422d8182c/chart/dcf/query-dGhlbWU9bGlnaHQ" alt="" original-src="https://images.simplywall.st/company/9596c81c-53d8-4dbe-bd4f-a13422d8182c/chart/dcf?theme=light"/></p>
<p>TASE:NYAX Discounted Cash Flow as at Jul 2025</p>
<div class="lb-trans"><p>TASE:NYAX 截至 2025 年 7 月的折現現金流</p>
</div><h2>Rorze (TSE:6323)</h2>
<div class="lb-trans"><h2>Rorze (TSE:6323)</h2>
</div><p><strong>Overview:</strong> Rorze Corporation specializes in designing, developing, manufacturing, and selling automation systems for semiconductor and flat panel display production globally, with a market cap of ¥339.54 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> Rorze Corporation 專注於全球半導體和液晶顯示器生產的自動化系統的設計、開發、製造和銷售，市值為 3395.4 億日元。</p>
</div><p><strong>Operations:</strong> Revenue Segments (in millions of ¥): Semiconductor production automation systems ¥68,000; Flat panel display production automation systems ¥12,500.</p>
<div class="lb-trans"><p><strong>運營：</strong> 收入部門（以百萬日元計）：半導體生產自動化系統 680 億；液晶顯示器生產自動化系統 125 億。</p>
</div><p><strong>Estimated Discount To Fair Value:</strong> 25.7%</p>
<div class="lb-trans"><p><strong>公允價值的估計折扣：</strong> 25.7%</p>
</div><p>Rorze is trading at ¥1992, below its estimated fair value of ¥2681.68, reflecting undervaluation based on cash flows. Despite a recent decline in profit margins to 15.7% from 23.4%, earnings are forecast to grow at 16% annually, outpacing the Japanese market's growth rate of 7.6%. The company recently completed a share buyback worth ¥1.98 billion, potentially enhancing shareholder value amidst high volatility in its share price over the past three months.</p>
<div class="lb-trans"><p>Rorze 的交易價格為 1992 日元，低於其估計的公允價值 2681.68 日元，反映出基於現金流的低估。儘管最近利潤率從 23.4% 下降至 15.7%，但預計年盈利將以 16% 的速度增長，超過日本市場 7.6% 的增長率。該公司最近完成了價值 19.8 億日元的股票回購，可能在其股價在過去三個月的高波動中提升股東價值。</p>
</div><ul>
<li>Insights from our recent growth report point to a promising forecast for Rorze's business outlook.</li>
<li>Click here to discover the nuances of Rorze with our detailed financial health report.</li>
</ul>
<div class="lb-trans"><ul>
<li>我們最近的增長報告的見解表明 Rorze 的商業前景樂觀。</li>
<li>點擊這裏通過我們的詳細財務健康報告發現 Rorze 的細微差別。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/4d659f8c-73ac-4638-abf7-18dec4e4fb14/chart/dcf/query-dGhlbWU9bGlnaHQ" alt="" original-src="https://images.simplywall.st/company/4d659f8c-73ac-4638-abf7-18dec4e4fb14/chart/dcf?theme=light"/></p>
<p>TSE:6323 Discounted Cash Flow as at Jul 2025</p>
<div class="lb-trans"><p>TSE:6323 截至 2025 年 7 月的折現現金流</p>
</div><h2>Summing It All Up</h2>
<div class="lb-trans"><h2>總結</h2>
</div><ul>
<li>Delve into our full catalog of 469 Undervalued Global Stocks Based On Cash Flows here.</li>
<li>Are any of these part of your asset mix? Tap into the analytical power of Simply Wall St's portfolio to get a 360-degree view on how they're shaping up.</li>
<li>Join a community of smart investors by using Simply Wall St. It's free and delivers expert-level analysis on worldwide markets.</li>
</ul>
<div class="lb-trans"><ul>
<li>深入瞭解我們基於現金流的 469 只被低估全球股票的完整目錄。</li>
<li>這些股票中有哪幾只在你的資產組合中？利用 Simply Wall St 的投資組合分析工具，全面瞭解它們的表現。</li>
<li>通過使用 Simply Wall St，加入聰明投資者的社區。它是免費的，並提供全球市場的專家級分析。</li>
</ul>
</div><h2>Curious About Other Options?</h2>
<div class="lb-trans"><h2>對其他選擇感興趣？</h2>
</div><ul>
<li>Explore high-performing small cap companies that haven't yet garnered significant analyst attention.</li>
<li>Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.</li>
<li>Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.</li>
</ul>
<div class="lb-trans"><ul>
<li>探索尚未獲得顯著分析師關注的高表現小型公司。</li>
<li>通過提供可靠收入來源的穩健分紅股票來多樣化你的投資組合，以應對潛在的市場動盪。</li>
<li>通過分析師和管理層的樂觀展望，推動你的投資組合中顯示出強勁增長潛力的公司。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation.</strong> We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>這篇來自 Simply Wall St 的文章具有一般性。<strong>我們僅基於歷史數據和分析師預測提供評論，採用無偏見的方法，我們的文章並不旨在提供財務建議。它不構成買賣任何股票的推薦，也未考慮您的目標或財務狀況。</strong> 我們旨在為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中沒有持倉。</em></p>
</div>

三隻全球股票被估計低估了最多 29.9%